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Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in
significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical
use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of
SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is
denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone
resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium,
alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including
enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in
development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has
resulted in great strides in preventing one of the most significant sources of complications of bone metastases.

1. Introduction
Prostate cancer remains the most common noncutaneous
cancer among American men [1]. More than 90% of patients
with metastatic castrate resistant prostate cancer (mCRPC)
develop bone metastases which results in a significant
increase in the risk of morbidity and mortality [2, 3]. The
extent of bone involvement in mCRPC has been also found
to be associated with patient survival [4]. While most patients
are clinically asymptomatic, those with symptoms may manifest with either pain or as skeletal-related events (SREs).
SREs are defined variably but typically include manifestations
of spinal cord compression, pathological fractures, hypercalcemia of malignancy, requirement for interventions such
as bone surgery, or need for bone radiation. Historically, in
the absence of bone-targeted therapy, the rate of SREs at 15
months was reported to be 44%, including a 22% rate of
fracture [5, 6]. While the mechanisms and lesions in mCRPC
have traditionally been thought of as osteoblastic, increasing
evidence lends credence to the importance of osteolytic and

proosteoclastogenic factors in prostate cancer metastases,
which brings about evidence of both an osteolytic and an
osteoblastic component with increased bone formation and
resorption [7]. Docetaxel, the standard first-line chemotherapy agent in mCRPC, not only improves overall survival (OS)
but also improves quality of life and significantly reduced pain
(35% versus 22% in placebo, 𝑃 = 0.01) [8, 9]. Increasing
recognition of the beneficial effects of agents that delay SREs
in the absence of objective overall survival has brought about
the routine use of bone-targeted agents (see Figure 1 for
mechanisms of action). Certainly, with the advent and use of
newer treatment agents such as the CYP17 lyase inhibitor abiraterone acetate and anti-androgen enzalutamide, decreased
rate of SREs is being reported with targeting of cancer cell
proliferation by these selective agents having effect also on
pain response [10–15]. This review describes the bone-targeted therapies that are either established or in development
in the treatment of mCRPC (see Table 1 for summary of
agents).
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Figure 1: Simplified figure of selected bone-targeted therapies in mCRPC and their targets. Zoledronic acid binds to hydroxyapatite crystals
preventing the activity of osteoclasts and stimulating osteoblast. Denosumab binds to RANKL preventing the binding of RANKL to RANK
thus inhibiting activation of osteoclasts. Radiopharmaceuticals emit 𝛼 or 𝛽 ionizing radiation to the tumor cell in the bone.
Table 1: Characteristics of selected FDA-approved bone targeting agents in mCRPC.
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2. Bisphosphonates
Bisphosphonates were the first class of agents investigated for
prevention of SREs in patients with mCRPC. Bisphosphonates are pyrophosphate analogues that adhere to hydroxyapatite crystal-binding sites in the bone matrix [22]. Through
attachment to binding sites in areas of active resorption,
bisphosphonates prevent osteoclast adherence while inhibiting osteoclast progenitor differentiation and survival through
stimulation of osteoblasts [23]. Zoledronic acid is currently
the only bisphosphonate approved to prevent SREs in patients
with metastatic CRPC. The phase 3, randomized, placebocontrolled trial, which led to the United States Food and Drug
Administration (FDA) approval, was conducted in a total of
643 patients with CRPC and asymptomatic bone metastases
and were randomized to receive intravenous zoledronic acid
at 4 mg, 8 mg, or placebo every 3 weeks for 22 cycles [5]. However, the dose was changed to 4 mg for all participants midway
due to concern for renal impairment developing in the highdose group. The primary endpoint of the study was the proportion of patients who develop SREs. Secondary endpoints
included time to the first SRE, skeletal morbidity rate, time to
disease progression, objective bone response, biochemical
markers, and quality of life parameters. The trial met the primary endpoint with results significant for the zoledronic acid
arm being associated with a reduced proportion of patients
with an SRE (44.2% versus 33.2%; 𝑃 = 0.021). However,
there was no significant difference in overall survival, disease
progression, performance status, or quality of life. With a
follow-up at 24 months, zoledronic acid decreased the risk of
SREs by 36% (Relative Risk (RR) = 0.64, 𝑃 = 0.002), increased
the time to first SRE by 167 days (488 days versus 321 days, 𝑃 =
0.009), and decreased bone pain (−0.47% difference on the
bone pain index at 24 months, 𝑃 = 0.024) as compared
to placebo [6]. Studies of other bisphosphonates have not
yielded similar results. Two multicenter, randomized, placebo-controlled trials to evaluate efficacy of pamidronate
in CRPC failed to show a reduction in SREs in patients
with metastatic prostate cancer and bone pain [24], with
results of these two studies reported together. A total of
350 patients with CRPC and painful bone metastases were
randomized to receive intravenous pamidronate (90 mg) or
placebo every 3 weeks for 27 cycles. Pamidronate is less potent
than zoledronic acid, which may account for the lack of
efficacy observed in these trials. Additionally, the patient population had more advanced metastatic disease at baseline with
painful rather than asymptomatic bone metastases. Similarly,
a study of clodronate to evaluate efficacy for palliation of
symptomatic bone metastases failed to demonstrate significant pain relief in men with CRPC and bone metastases [25].
Although another trial of oral clodronate versus placebo conducted by the Medical Research Council showed a nonstatistically significant favorable bone progression-free survival
with the use of clodronate [26], longer term follow-up of the
PR05 trial showed overall survival as a secondary endpoint
was statistically significant in the men who received clodronate [27], alluding to an inherent antitumor role of bisphosphonates [28].
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Bisphosphonates are fairly well tolerated, with adverse
effects including flu-like symptoms such as fatigue, myalgias,
and fever, particularly with the first infusions in up to 44%,
hypocalcemia in 6%, and osteonecrosis of the jaw (ONJ) in
1% of patients. It remains unclear how bisphosphonates bring
about ONJ although certain risk factors have been described
which include duration of bisphosphonate use, frequency of
use, and poor dental hygiene or intervention [29]. Other
reports include use of additional therapy such as corticosteroids or potential additive agents [30, 31]. It is therefore
imperative to obtain baseline dental consultations prior to
initiating bisphosphonates to determine whether major dental procedures need to be undertaken and avoidance of major
surgical dental procedures should be observed once bisphosphonates are already started or being given. Bisphosphonateinduced nephrotoxicity limits their use in many cases and
requires careful monitoring and dose-adjustment in patients
with renal insufficiency [32]. Given the long potential skeletal
half-life of bisphosphonate use [33], the optimal duration of
bisphosphonate use is unknown and remains an important
question to be answered in view of the potential side effects
that may be incurred with prolonged use.

3. Denosumab
Recent evidence has suggested that development of prostate
cancer bone metastases entails osteoclastic activity in addition to osteoblastic activity. Conceivably, the most clinically
important proosteoclastogenic factor by prostate cancer cells
is receptor activator of NF kappaB ligand (RANK-L) [7].
RANK-L is a tumor necrosis family (TNF) member that is
expressed on the surface of osteoblasts and is released by activated T cells. When RANK binds to RANK-L, it stimulates
osteoclast formation, activation, adherence, and survival,
eventually leading to bone resorption [34–38]. RANK-L is
counteracted by naturally occurring osteoprotegerin (OPG),
another TNF family member that binds and subsequently
prevents activation of its single cognate receptor, RANK,
thus, making osteoclastic activity dependent on the balance
between both RANK-L as well as OPG [39]. Denosumab is
a fully humanized monoclonal antibody that binds to the
RANK-L thereby inhibiting RANK-L mediated bone resorption. Denosumab was approved by the FDA in November
2010 for prevention of SREs in patients with bone metastases
from solid tumors, including those from prostate cancer. In
early clinical trials with humans, two phase I trials were conducted with denosumab in cancer patients with breast cancer
and multiple myeloma evaluating safety, pharmacokinetics,
and pharmacodynamics [40]. Denosumab exhibited nonlinear, dose dependent pharmacokinetics with rapid and prolonged absorption detectable as early as 1 hour post-dose and
average maximum concentration between 7 and 21 days postdose. In 2009, results from a phase II trial of denosumab in
patients with bone metastases from prostate cancer as well as
other neoplasms after intravenous (IV) bisphosphonate (BP)
therapy showed fewer patients receiving denosumab experienced on-study SREs than those receiving IV BPs. A total of
111 eligible patients were accrued with entry criteria of histologically confirmed malignancy, >1 bone metastasis, and
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urinary N-telopeptide (uNTx) levels higher than 50 nmol/L
bone collagen equivalents (BCE)/mM creatinine despite
ongoing IV BPs [41]. Elevated uNTx level, a marker for
bone resorption, has also been shown to be an independent
prognostic factor for overall survival in patient with bone
metastases from castrate resistant prostate cancer receiving
bisphosphonate therapy [42]. To further determine the effects
of denosumab on bone mineral density and fractures in men
receiving androgen deprivation therapy for prostate cancer,
a randomized, double-blinded, multicenter study, known as
the HALT prostate cancer trial, assigned men to receive denosumab at a dose of 60 mg subcutaneously every 6 months
or placebo, with the primary endpoint, percent change in
BMD at the lumbar spine at 24 months. At 24 months,
denosumab was associated with increased BMD at all sites
including lumbar spine, femoral neck, and total hip, as well as
a reduction in the incidence of new vertebral fractures among
men receiving ADT for nonmetastatic prostate cancer [43].
This pivotal trial eventually led to the FDA-approval of the use
of denosumab for men with nonmetastatic prostate cancer
receiving androgen deprivation therapies who are at high risk
for developing fractures. Two randomized, double-blinded
clinical trials have investigated the efficacy of subcutaneous
denosumab in prostate cancer [16, 44]. A phase III, randomized, double-blinded trial comparing denosumab with
zoledronic acid for prevention of SREs in men with bone
metastases from CRPC was conducted with a total of 1904
patients randomized [16]. Of the 950 patients assigned to
denosumab, the median time to first SRE was 20.7 months
compared to 17.1 months in the 951 patients assigned to zoledronic acid (𝑃 = 0.0002 for noninferiority and 𝑃 = 0.008 for
superiority, HR 0.82). Adverse events were similar in both
groups, though more events of hypocalcemia occurred in
the denosumab group than in the zoledronic acid group 13%
versus 6%, 𝑃 < 0.0001). This registration trial led to the FDAapproval of denosumab with the indication of prevention
of skeletal-related events in men with metastatic prostate
cancer. Another subsequent phase III, randomized, doubleblinded, placebo-controlled trial, specifically gauging bonemetastasis-free survival in men who are at high risk of developing bone metastasis (i.e., those with a PSA of ≥8.0 𝜇g/L or
PSA doubling time of ≤10.0 months, or both), as determined by time to first occurrence of bone metastasis (symptomatic or asymptomatic) or death from any cause [44] was
conducted and enrolled 1432 patients who were randomly
assigned to treatment groups. Though no difference in overall
survival was seen between groups, denosumab was shown
to significantly increase bone-metastases-free survival by a
median of 4.2 months as well as significantly delay time to
first bone metastases compared with placebo. However, these
endpoints were not deemed clinically significant enough such
that the FDA ruled against approval of denosumab for specific
use for this particular indication of delaying bone metastases.

4. Radiopharmaceuticals
Bone-seeking radiopharmaceuticals have historically been
available but relegated as a palliative treatment for pain in

Prostate Cancer
patients with metastatic prostate cancer [45]. Radiopharmaceuticals emit either alpha or beta particles. An alpha particle,
which is ejected from a heavy nucleus during alpha decay,
consists of two neutrons and two protons. A beta particle is an
electron released from a nucleus containing excess neutrons
during beta decay, in which one neutron is converted to a
proton, an electron, and a neutrino. Both 𝛼- and 𝛽-particles
can deliver damaging radiation locally to cancerous cells
[46]. Several 𝛽-emitting radiopharmaceuticals (strontium89, 153Sm-EDTMP, and Re-186 HEDP) are approved for palliation of pain caused by bone metastases from prostate cancer.
The most prominent limitation of these agents is myelosuppression. Radiopharmaceuticals are underutilized in clinical practice, mainly because of the concern for significant
myelosuppression, the dependency on other subspecialists
(i.e., nuclear medicine specialists or radiation oncologists)
for administration, and because until results on alpharadin
has emerged, no survival advantage was supported by clinical
data.
4.1. 89Sr and 153Sm. The most commonly used radiopharmaceuticals, both 𝛽-emitters, initially approved in the US
for treatment of bone metastases are Strontium-89 chloride
or 89Sr (Metastron; GE Healthcare, Arlington Heights, IL)
and Samarium-153 or 153Sm (Quadramet; EUSA Pharma,
Oxford, UK). There was no demonstration of improvement in
overall survival in Phase III trials, although palliative benefits
were seen that formed the basis of US FDA approval [17–
19, 47–50]. Although there is some evidence that these betaemitting radioisotopes might provide a small benefit with
complete reduction in pain over 1–6 months and no increase
in analgesic use, severe adverse effects (mainly leukopenia
and thrombocytopenia) are relatively frequent [51].
Sr-89 was initially FDA approved in 1993 as the first betaemitting radiopharmaceutical for metastatic prostate cancer.
Sr-89 is a divalent ion that is incorporated into the inorganic
matter of bone when injected intravenously, its half-life is
50.5 days with a beta energy of 1.5 MeV, without emission of
gamma energy, and is renally excreted rapidly [52, 53].
Several studies have investigated the relationship between
the dose of Sr-89 and clinical responses in terms of bone pain
palliation. A phase I/II study reported mean time-to-onset
of response at 9 days with average duration-of-response of
1.6 months in patients receiving doses ranging from 1.0 to
4.0 mCi/kg [54]. In contrast, another study reported no doseresponse relationship with increasing Sr-89 doses from 1.5 to
3.0 MBq/kg [52]. A systematic review summarized the efficacy of Sr-89 and reported that complete pain response varied
from 8% to 77% with a mean value of 32% [53]. The mean percentage of patients with a partial pain response was 44% with
a time delay until the onset of treatment effect varying from
4 to 28 days, with the mean duration of response lasting 15
months. Reduction in analgesic use was between 71% and 81%.
The principal toxicity of strontium-89 is hematologic in
nature, with an average reduction in white blood cells (WBC)
of 15% and platelet count of 25–45% in patients receiving the
recommended dose of 4.0 mCi or 150 MBq [52, 55]. Predicted
nadirs occur at around 6 weeks, and count recovery can take
up to 6 months.
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153Sm conjugated to ethylene-diamine-tetra-methylenephosphonic acid (EDTMP) was FDA approved in 1997 at a
dose of 1 mCi/Kg. The half-life is 1.9 days and pain relief is
rapid, generally between 2 and 7 days [18, 56]. Gamma emission is 103 keV, allowing for scintigraphic imaging, and indeed,
images strongly correlate with conventional technetium-99
bone scans. However, marrow toxicity remains the principal
side effect. Platelet and white cell counts go down between
3 and 6 weeks and generally recover by 8 weeks [19, 56].
Across three randomized trials using a single administration
of samarium-153 1.0 mCi/kg, grade 3+ thrombocytopenia was
3–15% and grade 3+ neutropenia was 5–14% [18, 19, 57]. At
standard doses, mean platelet reductions were 43–45% and
mean WBC declines were 49–51% of baseline [18, 57]. As
such, most clinical trials have used hematologic parameter
limitations at trial entry. Other contraindications to the use
of beta-emitting radiopharmaceuticals include radiotherapy
within the previous 2 months, impending cord compression
or pathologic fracture, significant renal insufficiency, Karnofsky Performance Status <50%, and disseminated intravascular coagulation.
Since single dose of 153Sm has demonstrated palliative
responses, the tolerability of repeated dosing has also been
explored. 153Sm can be administered safely and effectively
with repeat dosing of 1.0 mCi/kg [20]. In patients receiving
two or more doses of 153Sm, time to platelet, or WBC
nadir did not change after the first dose. 12% experienced
grade 3+ thrombocytopenia and recovery to a platelet count
975,000/mm3 occurred by week 8 in 90.4% of patients.
4.2. Radium 223. Alpharadin (Radium 223; 223Ra), marketed as Xofigo; Bayer Health Pharmaceuticals, Wayne, NJ,
is an 𝛼-particle emitter with high affinity for the bone
matrix and forms complexes with hydroxyapatite at areas of
increased bone turnover. 𝛼-particle emitters deliver a more
localized radiation with very short ranges of <100 𝜇m than do
𝛽-emitters. They have higher mutagenic and lethality potential effects through DNA damage [58]. It is excreted through
the gastrointestinal tract with a half-life of 11.4 days and low
gamma irradiation [59, 60]. Moreover, it is unique in comparison to beta emitters in that it delivers high linear energy with
very small track length (<0.1 mm in tissue) and subsequently
far less myelosuppression to the bone marrow. An early phase
I trial that included 15 prostate cancer patients examined the
feasibility and safety of 223Ra in the treatment of skeletal
metastases in prostate and breast cancer patients [60]. The
findings showed a remarkable median decline in the serum
alkaline phosphatase average of up to 52%. Given the associated pain relief, tolerability, and the rapidity of clearance from
the bloodstream, further phase II trial was initiated in men
with mCRPC who had pain requiring external beam radiotherapy [59] with promising results leading to the initiation of
the global phase III trial ALSYMPCA.
The ALSYMPCA trial (ALpharadin in SYMptomatic Prostate CAncer) is the first randomized phase III trial to demonstrate improved overall survival with a bone-seeking radioisotope [21]. A total of 922 patients with mCRPC across 19
countries were recruited. All patients were required to have
progressed with symptomatic bone metastases with at least
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2 metastatic sites on scintigraphy in the absence of visceral
metastases. All recruited patients had either received previous docetaxel, refused docetaxel, or were ineligible for docetaxel.
Randomization was 2 : 1 in a double-blind fashion to
receive 6 cycles of intravenous 223Ra on a 4-week schedule
with best standard of care or 6 infusions of placebo with best
standard of care. The trial was halted early after a planned
interim analysis found a survival benefit in favor of 223Ra.
Updated analysis has demonstrated a 3.6-month survival
advantage (14.9 versus 11.3 months, resp., 𝑃 = 0.00185, HR =
0.695). The study therefore met its primary endpoint. In
addition, the frequency of skeletal-related events was reduced
in the 223Ra group, and the median time to a SRE increased
(15.6 versus 9.8 months). Radium-223 is also less toxic than
the previous generation of bone-seeking radionuclides. It was
well tolerated with low rates of grade 3/4 neutropenia (1.8%
versus 0.8%) and thrombocytopenia (4% versus 2%). This
trial formed the basis of approval by the FDA of alpharadin
on May 15, 2013 for patients with symptomatic mCRPC to the
bones in the absence of visceral metastases. The recommended dose and schedule for alpharadin is 50 kBq/kg
(1.35 microcuries/kg) administered by slow intravenously
over 1 minute every 4 weeks for 6 doses. Given the potential
for hematologic toxicity with about 2% of patients in the
alpharadin arm sustaining bone marrow toxicity and pancytopenia, certain parameters are required prior to first administration, with absolute neutrophil count ≥ 1.5 × 109 /L and,
hemoglobin ≥ to 10 g/dL and platelet count greater than or
equal to 100 × 109 /L. The ability to utilize Radium 223 in the
clinic may shift the paradigm with regard to the use of radiopharmaceuticals such that it may truly be a viable treatment
option even in men before chemotherapy unlike older radiopharmaceuticals that have usually been relegated to use in the
end-of-life care setting. While there are no current guidelines that would dictate optimal sequencing strategies that
incorporates the use of radiopharmaceuticals with contemporary agents, the role of radiopharmaceuticals, specifically
Radium 223, is anticipated to increasingly gain preference
especially in the setting of symptomatic or asymptomatic
patients presenting with predominantly bony metastases with
the feasibility of continuation of concomitant androgen-biosynthesis inhibitors or antiandrogens.
4.3. Combination with Other Agents. In combining a radiopharmaceutical with chemotherapy to enhance antitumor
effects, several phase I/II trials have explored the use of
repeated doses of samarium-153 in combination with increasing doses of docetaxel. These trials did not reach dose limiting
toxicity [61, 62]. Thus, one can perhaps reap the benefits of
one agent known to increase survival (docetaxel) and use this
concurrently with a radiopharmaceutical known to improve
bone pain, thereby extending life and improving pain. However, the use of combination agents still requires caution, and
only in a clinical trial setting. Recent data presented at the
2013 American Society of Clinical Oncology (ASCO) Annual
meeting showed feasibility of combining docetaxel and alpharadin, though need for dose reduction of both agents [63].
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Some studies have suggested a potential for the combination of radiopharmaceuticals with other systemic therapies
[64]. Combination therapy is under study in two notable
phase 3 trials. A US National Cancer Institute–sponsored
study combines strontium-89 with either docetaxel with
prednisone or the ketoconazole, adriamycin, vinblastine, and
estramustine regimen (NCT00024167). Similarly, the UK
TRAPEZE trial randomized men with CRPC metastatic to
bone to receive one of four regimens: (1) docetaxel with prednisolone; (2) docetaxel, prednisolone, and zoledronic acid; (3)
docetaxel, prednisolone, and strontium-89; or (4) docetaxel,
prednisolone, zoledronic acid, and strontium-89. The rationale behind the trial stems from early data on the use of zoledronic acid which was not widely used in the UK as well as the
palliative effects of strontium as well as to achieve a consolidation effect after chemotherapy as a radionuclide [65]. The
results of the trial were recently presented at the 2013 ASCO
Annual meeting [66]. A total of 757 patients were randomized
to one of the four regimens and the primary outcomes of the
study were clinical bony PFS which is a composite endpoint
of bone pain progression, development of a clinical SRE
(no blinded or protocol-mandated radiologic assessment) or
death as well as cost-effectiveness, with the former endpoint
being reported. Secondary outcomes were SRE-free interval,
PSA progression-free survival, toxicity, total SREs, and OS.
After 6 cycles of docetaxel, Sr-89 improved CPFS (HR =
0.845, 𝑃 = 0.036). Not surprisingly, no overall survival benefit
was seen. While the zoledronic acid arm did not show
improved CPFS (as a primary outcome) or OS, it showed
improvement in SRE-free interval from 13.1 to 18.1 months
whereas the strontium arm did not show statistically significant SRE-free interval. While the findings suggest a potential
role of Sr-89 as postchemotherapy maintenance, the specific
therapeutic benefit of this radiopharmaceutical may be limited especially in light of the more contemporary radiopharmaceutical with the use of alpharadin that has shown overall
survival in addition to traditional SRE effects.

5. Select Agents with Bone-Targeted Effects
5.1. Cabozantinib. Cabozantinib (formerly XL-184, Cometriq,
Exelixis, San Francisco, CA) is a novel receptor tyrosine
kinase inhibitor that inhibits the hepatocyte growth factor
c-Met and the vascular endothelial growth factor receptor 2
(VEGFR2), among other pathways. In a phase II randomized
discontinuation trial, cabozantinib resulted in partial resolution of bone lesions in 56% of patients and complete resolution in 19% of the patients [67]. These objective responses correlated with pain and bone turnover markers 55% of patients
had declines of ≥50% in plasma C-telopeptide, and 56% of
patients with elevated total alkaline phosphatase had declines
of ≥50% and of the 28 patients receiving narcotics for bone
pain, 64% had improvement in pain intensity and 46% were
able to decrease or discontinue narcotics. In another dosefinding phase II trial using cabozantinib that looked at 3
varying doses of 60, 40, and 20 mg with a primary endpoint of
week 6 bone scan response, defined as ≥30% decrease in bone
scan lesion area, the dose of 40 mg was found to be associated
with a high rate of bone scan response with better tolerability
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compared to the 100 mg dose [68]. Whether the radiographic
bone responses translate into a survival benefit and durable
clinical response will be determined in upcoming phase III
trials. The promising results have prompted the phase III
study known as COMET-2 (CabOzantinib MET Inhibition
CRPC Efficacy Trial) of cabozantinib versus mitoxantrone
and prednisone to demonstrate a primary endpoint of pain
reduction [ClinicalTrials.gov identifier: NCT01522443]. A
separate phase III trial, COMET-1, will assess for OS [ClinicalTrials.gov identifier: NCT01605227]. Cabozantinib is a
promising agent given its oral administration, its effect on
pain and bone scans, and its unique targeted pathway.
5.2. Dasatinib. Dasatinib (Sprycel, Bristol-Myers-Squibb,
Princeton, NJ) is a tyrosine kinase inhibitor that inhibits Src,
a mediator of osteoclastic activity, tumor growth, and metastases [69]. In a phase I/II trial of dasatinib combined with
docetaxel, 30% (𝑛 = 14) of patients had disappearance of a
lesion on bone scan and another 41% (𝑛 = 19) had stable bone
scans. Bone markers also declined in >75% of patients (87%
experienced urine N-telopeptide declines and 76% had
decreases in bone-specific alkaline phosphatase levels) [70].
Similarly, a phase II trial with dasatinib monotherapy yielded
encouraging activity in the bone with reduction in urinary
N-telopeptide in half of evaluable patients with lack of progression in 24 weeks in 43% of patients [71]. Results detected
in the bone prompted a phase III, multinational, randomized,
double-blinded, placebo-controlled trial (READY) with a
primary endpoint of overall survival, and secondary endpoints of SRE and pain. However, this study was recently
reported at the Genitourinary Cancers Symposium and
showed no difference in overall survival with a median OS of
21.5 months in the combination arm versus 21.2 months in the
dasatinib/placebo arm (hazard ratio [HR], 0.99; log-rank 𝑃 =
0.90) [72]. Further analyses of whether the changes in bone
markers reflect only bone resorption changes or true tumor
dynamic changes are ongoing and recently reported [73].
5.3. Abiraterone Acetate. Abiraterone acetate (Zytiga, Janssen/Ortho-Biotech, Horsham, PA) is an inhibitor of CYP17
that functions as an androgen biosynthesis inhibitor that is
currently approved in both pre- and postdocetaxel setting of
mCRPC. The pivotal COU-301 study showed improvement in
overall survival in the abiraterone with prednisone arm at 14.8
months versus 10.9 months in the prednisone only arm, with a
35% reduction in the risk of death in the abiraterone arm [15].
In addition, effective pain palliation and prevention of SREs
have also been reported [12]. At a follow-up of 20 months,
the median time to occurrence of first SRE was longer with
abiraterone acetate and prednisone at 25 months compared
to 20.3 months in the prednisone only arm. Similarly, abiraterone acetate and prednisone resulted in significantly more
palliation in 157 of 349 (45.0%) of patients versus 47 of 163
(28.8%) in those patients with clinically significant pain at
baseline. Notably faster palliation was achieved with abiraterone and prednisone with a median time to palliation of
5.6 months versus 13.7 months in those who did not receive
abiraterone. In the COU-302 trial, abiraterone acetate plus
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Table 2: The effect of selected agents on skeletal-related events (SREs) and pain palliation response based on randomized clinical trials.
Agent

SRE (% incidence or time to SRE)

Pain palliation response

Docetaxel versus mitoxantrone [8]
Abiraterone acetate versus placebo [12, 13]
Enzalutamide versus placebo [11, 14]
Cabazitaxel versus mitoxantrone [74]

NE
25.0 versus 20.3 months (𝑃 = 0.0001)
16.7 versus 13.3 months (𝑃 < 0.0001)
NE
33.2% versus 44.2% (𝑃 = 0.021), 14.9
months versus 10.7 months (𝑃 = 0.002)
20.7 versus 17.1 months (𝑃 = 0.0008)

35% versus 22% (𝑃 = 0.01)
45% versus 28.8% (𝑃 = 0.005)
NR
9.2% versus 7.7% (𝑃 = 0.63)

NE

Zoledronic acid versus placebo [5]

−0.47% bone pain index (𝑃 = 0.024)

Denosumab versus zoledronic acid [16]
Denosumab versus placebo
(non-mCRPC) [44]
Sm-153 versus placebo [18]

29.5 versus 25.3 months (𝑃 = 0.0028)

NE

NE

Sr-89 [53]

NE

Ra 223 versus placebo [21]
Cabozantinib [67]

15.6 versus 9.8 months (𝑃 = 0.00046)
NE

72% pain relief (𝑃 < 0.034)
Mean complete pain response 32%, mean
partial pain response 44%
NE
64% improvement

NE: not examined and NR: not reported.

prednisone before docetaxel was shown to yield a significant improvement in radiographic progression-free survival
despite no improvement, though improved trend, towards
overall survival [75].
5.4. Enzalutamide. Enzalutamide (formerly MDV3100,
Xtandi, Astellas, Northbrook, IL; Medivation, San Francisco,
CA) is an antiandrogen currently approved for postdocetaxel
chemotherapy progression of mCRPC. The AFFIRM trial
showed an improvement in overall survival in men who
received enzalutamide with a median of 18.4 months versus
13.6 months in the placebo group [11]. While only a secondary
endpoint, enzalutamide has also been shown to retard SREs
with delayed time to the first SRE at 16.7 months versus 13.3
months in those who received placebo; hazard ratio, 0.69;
𝑃 < 0.001). In addition, all parameters of pain palliation,
including time to pain progression, mean reduction in pain
intensity as well as reduction in pain interference were all in
favor of the enzalutamide compared to the placebo arm [14].

6. Conclusion
The recent understanding of the molecular mechanisms of
bone metastases in mCRPC has resulted in the significant
development of new bone-targeted agents. Bone involvement
in mCRPC is a source of significant morbidity including pain
and SREs and targeting the bone microenvironment leads
to improvement of quality of life, reduction of bone complications, and more recently, improvement in survival with
a radiopharmaceutical. While specific bone-targeted agents
have been approved and used routinely in practice as prevention of skeletal-related events, contemporary therapeutic
agents that yield survival benefits in the form of novel androgen biosynthesis inhibitors or antiandrogens appear to have
similar efficacy in delaying skeletal-related events (see Table 2
regarding effects on palliation and SREs of various agents),
perhaps as a result of improved antitumor effects. The overarching question would be as follows: Is there a continued need

for specific bone-targeted agents when contemporary drug
therapies that have inherent antitumor, hence bone, effects
achieve the same purpose? The field of prostate cancer therapy is rapidly evolving. As clinical trials start incorporating
biomarker analyses with bone turnover markers and measuring specific bone-targeted endpoints, better understanding of
the interplay between specific drugs to harness the benefits
and obviate the side effects from these agents is becoming a
reality in prostate cancer therapy.
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